17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect …

G Girasole, RL Jilka, G Passeri… - The Journal of …, 1992 - Am Soc Clin Investig
G Girasole, RL Jilka, G Passeri, S Boswell, G Boder, DC Williams, SC Manolagas
The Journal of clinical investigation, 1992Am Soc Clin Investig
The effect of 17 beta-estradiol on interleukin-6 (IL-6) synthesis was examined in murine
bone marrow-derived stromal cell lines, normal human bone-derived cells, and
nontransformed osteoblast cell lines from mice and rats. In all these cell types IL-6
production was stimulated as much as 10,000-fold in response to the combination of
recombinant interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF alpha). Addition of 17
beta-estradiol in the cultures exerted a dose-dependent inhibition of IL-1-, TNF-, and IL-1+ …
The effect of 17 beta-estradiol on interleukin-6 (IL-6) synthesis was examined in murine bone marrow-derived stromal cell lines, normal human bone-derived cells, and nontransformed osteoblast cell lines from mice and rats. In all these cell types IL-6 production was stimulated as much as 10,000-fold in response to the combination of recombinant interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF alpha). Addition of 17 beta-estradiol in the cultures exerted a dose-dependent inhibition of IL-1-, TNF-, and IL-1 + TNF-induced production of bioassayable IL-6. Testosterone and progesterone (but not 17 alpha-estradiol) also inhibited IL-6, but their effective concentrations were two orders of magnitude higher than 17 beta-estradiol. 17 beta-estradiol also decreased the levels of the IL-6 mRNA. In addition, estradiol inhibited both TNF-induced IL-6 production and osteoclast development in primary bone cell cultures derived from neonatal murine calvaria. The TNF-stimulated osteoclast development was also suppressed by a neutralizing monoclonal anti-IL-6 antibody. This in vitro evidence suggests, for the first time, a mechanistic paradigm by which estrogens might exert at least part of their antiresorptive influence on the skeleton.
Images
The Journal of Clinical Investigation